Company news

Schrodinger, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Schrödinger to Present at UBS Global Healthcare Conference

October 28, 2026

Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 26, 2026

Schrödinger to Announce Third Quarter 2026 Financial Results on November 4

October 21, 2026

Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry

October 14, 2026

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

September 9, 2026

Schrodinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

August 6, 2026

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

August 5, 2026

Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery

July 27, 2026

Schrödinger to Announce Second Quarter 2026 Financial Results on August 5

July 22, 2026

Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 25, 2026

Schrödinger Reports First Quarter 2026 Financial Results

May 5, 2026

Schrödinger to Announce First Quarter 2026 Financial Results on May 5

April 21, 2026

Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

February 24, 2026

Schrodinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

February 12, 2026

Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

February 11, 2026

Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

January 12, 2026

Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

January 8, 2026

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 16, 2025

Schrödinger to Present at Jefferies London Healthcare Conference

November 5, 2025

Schrödinger Reports Third Quarter 2025 Financial Results

November 4, 2025

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

October 21, 2025

Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635c4

October 16, 2025

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

August 26, 2025

Schrödinger Announces Discontinuation of SGR-2921 Program

August 13, 2025

Schrödinger Reports Second Quarter 2025 Financial Results

August 6, 2025

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

July 24, 2025

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

July 16, 2025

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

June 26, 2025

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

June 11, 2025

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 28, 2025

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

May 28, 2025

Schrödinger to Present at Jefferies Global Healthcare Conference

May 21, 2025

Schrödinger Announces CFO Appointment

May 19, 2025

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

May 13, 2025

Schrödinger Reports Strong First Quarter 2025 Financial Results

May 6, 2025

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

May 4, 2025

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

April 27, 2025

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

April 22, 2025

Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

April 13, 2025

Schrödinger to Present Preclinical Data at AACR Annual Meeting

March 24, 2025

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

March 9, 2025

Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

February 25, 2025

Schrödinger to Participate in Upcoming Investor Conferences

February 23, 2025

Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26

February 11, 2025

Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities

January 12, 2025

Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference

November 19, 2024

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

November 17, 2024

Schrödinger Reports Third Quarter 2024 Financial Results

November 11, 2024

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

November 11, 2024

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

October 30, 2024

Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 21 decks. Every deck is listed under its year.